Description A medication used to treat low or no testosterone.
DrugBank ID DB13944
Modality Small Molecule
Patents 26
Indicated Conditions 3
Phase 0 1
Phase 1 14
Phase 2 23
Phase 3 11
Phase 4 8
Testosterone enanthate is an androgen used to treat low or absent testosterone.
Delatestryl, Xyosted
Generic Name Testosterone enanthate
DrugBank Accession Number DB13944
Testosterone enanthate is an esterified variant of testosterone that comes as an injectable compound with a slow-release rate. This slow release is achieved by the presence of the enanthate ester functional group attached to the testosterone molecule. This testosterone derivative was first approved on December 24, 1953.
In 2017, about 6.5 million retail prescriptions for testosterone therapy were filled. The majority of the prescriptions written were for injectable (66%) and topical (32%) testosterone products. As recent as 1 October 2018, the US FDA approved Antares Pharma Inc.'s Xyosted - a subcutaneous testosterone enanthate product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable autoinjector. As the first subcutaneous autoinjector product designed for testosterone replacement therapy, this innovative formulation removes transfer concerns commonly associated with testosterone gels and potentially reduces the need for in-office/in-clinic injection procedures that may inconvenience patients with frequent visits to the clinic.
Groups Approved, Investigational
Average: 400.594
Monoisotopic: 400.297745146
C 26 H 40 O 3
External IDs Not Available
Testosterone enanthate in males is indicated as a replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. Some of the treated conditions are 1) primary hypogonadism, defined as testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome or orchidectomy; 2) hypogonadotropic hypogonadism due to an idiopathic gonadotropin or luteinizing hormone-releasing hormone deficiency or due to a pituitary-hypothalamic injury from tumors, trauma or radiation, in this case it is important to accompany the treatment with adrenal cortical and thyroid hormone replacement therapy; 3) to stimulate puberty in patients with delayed puberty not secondary to a pathological disorder. If the conditions 1 and 2 occur pri
